Jefferies maintained a Buy rating on Myriad Genetics (NASDAQ: MYGN) and raised its price target to $33.00 (from $31.00). Myriad ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE